Keros Therapeutics (KROS) shares were down 72% pre-bell Thursday after the company said it voluntarily halted two treatment arms in a phase 2 study of cibotercept in combination with background therapy in patients with pulmonary arterial hypertension.
Samfine Creation (SFHG) stock was 36% lower, extending Wednesday's fall.
Intellinetics (INLX) shares were down 21% following a muted session.
Chatham Lodging Trust (CLDT) stock was 19% lower after closing nearly unchanged on Wednesday.
Myriad Genetics (MYGN) shares were down 17%, adding to Wednesday's losses.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments